KEROS THERAPEUTICS INC (KROS)

US4923271013 - Common Stock

17.03  +0.11 (+0.65%)

After market: 17.01 -0.02 (-0.12%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
20.1M
-100.00%
151K490.232K
224.66%
64.342K
-86.88%
23.006M
35,656.03%
61.978M
169.40%
167.3M
169.93%
385.72M
130.56%
708.28M
83.63%
1.228B
73.38%
EBITDA
YoY % growth
-55.99M
-20.72%
-114.12M
-103.82%
-169.126M
-48.20%
-205.361M
-21.42%
-234.067M
-13.98%
-238.387M
-1.85%
N/AN/AN/AN/AN/A
EBIT
YoY % growth
-56.37M
-20.81%
-114.79M
-103.64%
-169.941M
-48.05%
-219.797M
-29.34%
-251.027M
-14.21%
-265.742M
-5.86%
-236.921M
10.85%
-215.716M
8.95%
-80.848M
62.52%
136.19M
268.45%
560.53M
311.58%
Operating Margin
-280.45%N/A-112,543.71%-44,835.36%-390,147.43%-1,155.10%-382.27%-128.94%-20.96%19.23%45.65%
EPS
YoY % growth
-2.52
63.05%
-4.15
-64.68%
-5.20
-25.30%
-5.31
-2.09%
-5.26
0.99%
-4.77
9.17%
-4.59
3.86%
-2.68
41.59%
1.12
141.66%
3.59
221.31%
5.94
65.48%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth
-1.45
-8.58%
-1.44
-19.28%
-1.45
-16.08%
-1.42
-1.01%
-1.40
3.86%
-0.88
39.22%
-0.89
38.84%
-0.89
37.69%
-0.89
36.56%
Revenue
Q2Q % growth
47.073K
-67.08%
20.4K
-75.42%
20.4K
-44.86%
20.4K
-94.74%
25.5K
-45.83%
N/AN/AN/AN/A
EBITDA
Q2Q % growth
-63.883M
-39.97%
N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-60.28M
-29.76%
-62.367M
-28.64%
-63.24M
-25.38%
-64.498M
-9.96%
-66.302M
-9.99%
N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
-1.41
-6.02%
-1.30-0.11-8.05%
Q2 2024
Q2Q % growth
-1.25
1.57%
-1.260.010.53%
Q1 2024
Q2Q % growth
-1.21
3.97%
-1.370.1611.93%
Q4 2023
Q2Q % growth
-1.34
-22.94%
-1.400.064.43%
Q3 2023
Q2Q % growth
-1.33
-44.57%
-1.370.043.25%
Q2 2023
Q2Q % growth
-1.27
-12.39%
-1.370.106.98%
Q1 2023
Q2Q % growth
-1.26
-24.75%
-1.15-0.11-10.01%
Q4 2022
Q2Q % growth
-1.09
-263.33%
-1.120.032.60%
Q3 2022
Q2Q % growth
-0.92
-5.75%
-1.260.3426.77%
Q2 2022
Q2Q % growth
-1.13
-68.66%
-1.08-0.05-4.71%
Q1 2022
Q2Q % growth
-1.01
-48.53%
-0.88-0.13-14.81%
Q4 2021
Q2Q % growth
-0.30
38.78%
-0.940.6467.94%
Q3 2021
Q2Q % growth
-0.87
-45.00%
-0.74-0.13-18.05%
Q2 2021
Q2Q % growth
-0.67
-8.06%
-0.670.00-0.28%
Q1 2021
Q2Q % growth
-0.68
86.69%
-0.59-0.09-14.94%
Q4 2020
Q2Q % growth
-0.49 -0.580.0915.72%
Q3 2020
Q2Q % growth
-0.60 -0.610.011.14%
Q2 2020
Q2Q % growth
-0.62 -0.690.079.95%
Q1 2020
Q2Q % growth
-5.11 -0.38-4.73-1,254.00%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q2 2023
Q2Q % growth
165.75K-165.75K-100.00%
Q1 2023
Q2Q % growth
221.003K-221.003K-100.00%
Q4 2022
Q2Q % growth

-100.00%
874.283K-874.283K-100.00%
Q2 2022
Q2Q % growth

-100.00%
%
Q1 2022
Q2Q % growth
6.12M-6.12M-100.00%
Q4 2020
Q2Q % growth

-100.00%
%
Q3 2020
Q2Q % growth

-100.00%
63.75K-63.75K-100.00%
Q2 2020
Q2Q % growth

-100.00%
63.75K-63.75K-100.00%
Q1 2020
Q2Q % growth

-100.00%
84.997K-84.997K-100.00%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% -26.61% -0.72% -5.96%
Revenue0% -99.35% -75.63% -90.79%